Results for: Breast

40 Trials Avaliable

  • BRE 203

    A Phase II trial with TAK -700 in Metastatic breast cancer patients with tumors that express the Androgen Receptor (AR)

  • BRE 225

    A phase 1, open-label, dose escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

  • BRE 226

    A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer

  • BRE 237

    A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locallky Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regiments for Metastatic Disease

  • BRE 239

    A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer

  • BRE 253

    A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR)

  • BRE 260

    A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs.Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapiesand Require Systemic Treatment

  • BRE 268

    An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)

  • BRE 271

    Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

  • BRE 281

    Palbociclib and Endocrine therapy for LObular breast cancer Preoperative Study: A randomized phase II study of Palbociclib with letrozole versus letrozole alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

  • BRE 283

    A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE

  • BRE 285

    A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER

  • BRE 287

    A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer

  • BRE 292

    A PHASE 1, FIRST-IN-HUMAN, MULTI-PART STUDY OF RAD140 IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE BREAST CANCER

  • BRE 296

    A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

  • BRE 297

    A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER

  • BRE 298

    An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic (Stage IV) Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

  • BRE 300

    A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH HORMONE RECEPTOR'{POSITIVE HER2-NEGATIVE BREAST CANCER (MORPHEUS-HR+ BREAST CANCER)

  • BRE 302

    Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC

  • BRE 303

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

  • BRE 304

    A phase III, randomized, placebo-controlled, multicenter study of the efficacy and safety of atezolizumab plus chemotherapy in the treatment of early-relapsing locally recurrent inoperable or metastatic triple-negative breast cancer

  • BRE 305

    An Open Label Study of SC-005 in Subjects with Triple Negative Breast Cancer (TNBC)

  • BRE 308

    AN OPEN-LABEL, SINGLE-ARM PILOT STUDY EVALUATING THE ANTITUMOR ACTIVITY AND SAFETY OF NIRAPARIB AS NEOADJUVANT TREATMENT IN LOCALIZED, HER2-NEGATIVE, BRCA-MUTANT BREAST CANCER PATIENTS

  • BRE 311

    A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF DHES0815A IN PATIENTS WITH HER2-POSITIVE BREAST CANCER

  • BRE 312

    A multi-centre, double-blind, placebo-controlled, randomised phase III trial to compare efficacy and safety of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease

  • BRE 314

    A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination with Palbociclib in Women with Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

  • BRE 315

    ATOP TRIAL: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

  • BRE 317

    A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH TRASTUZUMAB AND TAXANE

  • BRE 319

    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER (IMpassion050)

  • BRE 320

    A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • BRE 321

    A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer

  • BRE 322

    A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).

  • BRE 324

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human EpidermalnGrowth Factor Receptor 2-Negative (ER+/HER2') Breast Cancer (KEYNOTE-756)n

  • MULTI 18

    A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease

  • OUTCOMES 02

    Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane use in Metastatic Breast Cancer

  • PRO 09

    A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

  • RM 456

    A Phase 1b, First in Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

  • RM 530

    OPEN-LABEL, DOSE ESCALATION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF RO6870810 AND ATEZOLIZUMAB (PD-L1 ANTIBODY) IN PATIENTS WITH ADVANCED OVARIAN CANCER OR TRIPLE NEGATIVE BREAST CANCER

  • RM 566

    A PHASE 1B, MULTICENTER, TWO-PART, OPENLABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2- EXPRESSING ADVANCED BREAST AND UROTHELIAL CANCER

  • RM 588

    A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER